


**Promab Biotechnologies' CAR-T new product development programs are being designed for pre-clinical and future clinical applications.**

**CAR-T cells can be used for:**

1. Compound screening
2. Antibody screening
3. Co-stimulatory and activation domain comparison
4. Personalized medicine and donor variations for CAR-T screening
5. Checkpoint inhibitors
6. Safety switches and regulators of CAR-T functions
7. Pre-clinical in vivo models
8. Treg and T memory cells in CAR-T setting
9. CAR-T signaling, tumor microenvironment
10. Proof of concept studies for clinical trials

**The structure of CAR from Promab's available CAR-T cells targeting CD133 antigen**

CD133 antigen also known as prominin-1 is a glycoprotein that in humans is encoded by the PROM1 gene. It is a member of pentaspan transmembrane glycoproteins, which localizes to cellular protrusions. CD133 is expressed in many types of tumors: glioblastoma, colon cancer, melanoma and other types of tumors and is considered one of the markers of cancer stem cells.



**Figure 1.** CAR-T cells expressing the above constructs are available from Promab targeting CD133 antigen. ScFv, single chain variable fragment. These CAR-T cells are generated with CD133 ScFv-CD28-CD3 $\zeta$  CAR construct.


## PM-CAR1018 CD133 SCFV-CD28-CD3 $\zeta$

Ready-to use-CAR-T cells

To date Promab generated 2nd or 3rd generation CAR and CAR controls (2nd generation of CAR is shown in Figure 1), CAR-T cells and CAR-Natural Killer (NK) effector cells against cancer target cells that show excellent functionality, including dose-dependent and target cell-specific cytotoxic activity (Figure 2).

These cells can be tested with CAR-T in cytotoxic assays and used for testing modulators of immune checkpoint inhibitors (PD-1, CTLA-4 pathways) or activators of immune response, small molecules affecting T cell or Treg activity.

### Data



**Figure 2.** Real-time cytotoxic activity of CD133 ScFv-CAR-T effector cells against CD133-positive target HT-29 colon cancer cells. The ratio of effector cells to target cells is 10:1.